HIV Vaccines
A section of Vaccines (ISSN 2076-393X).
Section Information
Aims
The aim of the section “HIV Vaccines” is to describe current experimental and conceptual advances in the development of HIV vaccines.
Scope
We will consider manuscripts investigating anti-HIV immunity, immunological responses to potential HIV vaccine antigens, the testing of HIV vaccine candidates in animals and humans, delivery methods of HIV vaccine antigens, studies of vaccine adjuvants related to HIV vaccine development, investigations of HIV vaccine strategies aimed to raise broadly neutralizing antibodies, and theoretical studies suggesting and rationalizing new types of HIV vaccine or new ways of stimulating protective anti-HIV immunity. The section will publish different types of manuscripts, including short definitive reports, full-size papers, and reviews. All submissions will undergo rigorous peer review.
Editorial Board
Special Issues
Following special issues within this section are currently open for submissions:
- Neutralizing Antibodies and Vaccine Development Against the HIV-1 Virus (Deadline: 31 May 2025)
- Novel HIV Immunization Regimens and Immune Implications (Deadline: 31 May 2025)
- Research on HIV/AIDS Vaccine (Deadline: 31 May 2025)
- The Need for an HIV Vaccine in the Era of Highly Effective PrEP (Deadline: 31 August 2025)
- Vaccine Against Sexually Transmitted Diseases (Deadline: 30 September 2025)
- HIV Vaccine Development and Clinical Trails (Deadline: 31 October 2025)
- Advances in HIV Vaccine Development, 2nd Edition (Deadline: 30 November 2025)
- T and B Cell Responses to HIV and Tuberculosis Infections/Coinfection and Vaccinations (Deadline: 31 December 2025)
- The Development of HIV Vaccines: Advances and Challenges (Deadline: 31 December 2025)
